Turvey Lab

@turveylab.bsky.social

Dr. Stuart Turvey and the Turvey lab are committed to improving child health through research. Our research transforms lives. There is urgency to what we do! We are based at UBC and BC Children's Hospital, Vancouver, Canada. 🇨🇦 https://turveylab.com/

@jhumimmunity.orgReposted by @turveylab.bsky.social

Stojcic et al. provide the first comprehensive description of the clinical phenotype and outcomes of all known patients w/ the heterozygous IRF4 p.T95R variant, analyzing 10 affected individuals and identifying shared clinical features, treatment responses & outcomes:
rupress.org/jhi/article/...

@esidsociety.bsky.socialReposted by @turveylab.bsky.social

One focused day of practical training. The Inborn Errors of Immunity: Spot, Screen, Support course helps healthcare and lab professionals recognise suspected IEI and know when to refer. CME accreditation is being applied for.

👉 Places limited, secure yours: https://bit.ly/4yNNJmd

@turveylab.bsky.social

Looking forward to #ESID2026!

Rare genetic disorders can teach us remarkable lessons about human immunity, and increasingly point the way toward precision treatments for allergic disease. Hope to see many of you there!

@esidsociety.bsky.social

@turveylab.bsky.social

Ultimate precision medicine! Delighted to have played a small part to ensure our patient from @bcchresearch.bsky.social was able to receive this remarkable curative treatment. Kudos to Dr. Elie Haddad for launching this trial in Canada. @nejm.org @genomecanada.ca @genomebc.bsky.social

CHEK News@cheknews.ca

Ty Sperle says he felt "insane shock" after learning he'd been cured of a rare genetic disease through a clinical trial using a new gene-editing treatment.

cheknews.caB.C. man cured of rare disease in world-first for new gene-editing technologyTy Sperle says he felt "insane shock" after learning he'd been cured of a rare genetic disease through a clinical trial using a new gene-editing treatment.
hresearch.bsky.socialBluesky
@turveylab.bsky.social

👏👏👏This is really a remarkable breakthrough in treating patients with chronic granulomatous disease👏👏👏 Proud to have played a very small part in this medical miracle. @bcchresearch.bsky.social @nejm.org @bcchf.bsky.social @ubcmedicine.bsky.social

NEJM.org@nejm.org

In a new study, gene editing with a prime editor was used to treat two persons with chronic granulomatous disease caused by a small deletion in the gene NCF1. Full study results: nej.md/49OCYqx #ASH25 | @ash.hematology.org